IONQ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
IONQ Inc is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong revenue growth, positive future outlook, and expanding quantum computing initiatives outweigh the short-term financial losses and mixed analyst ratings. The recent price surge and positive sentiment in the quantum computing sector further support this decision.
The MACD histogram is positive and expanding, indicating bullish momentum. However, the RSI is in the neutral zone at 76.09, and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level of 39.642, suggesting limited immediate upside but potential for long-term growth.
Fourth-quarter revenue surged 429% YoY, exceeding expectations.
Full-year 2026 revenue forecast surpasses Wall Street expectations.
Deployment of large-scale quantum networks in Europe and plans to acquire SkyWater Technology.
Rising investor interest in quantum computing, as reflected by the Defiance Quantum ETF surpassing $3.5 billion in assets.
Net income and EPS dropped significantly YoY in Q4
Gross margin remains negative, reflecting operational inefficiencies.
Wolfpack Research's short report raises concerns about lost Pentagon contracts and potential financial misrepresentation.
In Q4 2025, revenue increased by 428.52% YoY to $61.9 million. However, net income dropped by -473.11% YoY to -$753.67 million, and EPS declined by -334.41% YoY to 2.18. Gross margin also dropped significantly to -36.11%. Despite strong revenue growth, profitability remains a concern.
Analyst ratings are mixed. Jefferies and Mizuho maintain Buy ratings with high price targets ($90-$100), citing IonQ's leadership in quantum computing. JPMorgan and Morgan Stanley have Neutral and Equal Weight ratings, respectively, with lower price targets ($35-$42), reflecting concerns about long-term commercialization and valuation compression. Wolfpack Research's short report adds skepticism to the stock's outlook.
